AU2017253560B2 - Conjugates comprising RIPK2 inhibitors - Google Patents
Conjugates comprising RIPK2 inhibitors Download PDFInfo
- Publication number
- AU2017253560B2 AU2017253560B2 AU2017253560A AU2017253560A AU2017253560B2 AU 2017253560 B2 AU2017253560 B2 AU 2017253560B2 AU 2017253560 A AU2017253560 A AU 2017253560A AU 2017253560 A AU2017253560 A AU 2017253560A AU 2017253560 B2 AU2017253560 B2 AU 2017253560B2
- Authority
- AU
- Australia
- Prior art keywords
- dimethyl
- tert
- methyl
- oxy
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C*CC*(C[C@@]1*(CC(*(CC2(C)C)c3c2*(N)c(*)c(Cc2ccc(C)cc2)c3)=O)C[C@@](*)*(C)C1)C(C)C Chemical compound C*CC*(C[C@@]1*(CC(*(CC2(C)C)c3c2*(N)c(*)c(Cc2ccc(C)cc2)c3)=O)C[C@@](*)*(C)C1)C(C)C 0.000 description 3
- DJQXZAAVKICXIW-LLVKDONJSA-N CC(C)(C)OC(N1C[C@H](COc(cn2)cnc2Cl)OCC1)=O Chemical compound CC(C)(C)OC(N1C[C@H](COc(cn2)cnc2Cl)OCC1)=O DJQXZAAVKICXIW-LLVKDONJSA-N 0.000 description 1
- NNPSDWFWOCDUBT-MUUNZHRXSA-N CC(C)(C)OC(N1C[C@H](COc2cnc(N3CCN(CCCOc4cc5ncnc(Nc6c(C)c(C)n[nH]6)c5cc4S(C(C)(C)C)(=O)=O)CC3)nc2)OCC1)=O Chemical compound CC(C)(C)OC(N1C[C@H](COc2cnc(N3CCN(CCCOc4cc5ncnc(Nc6c(C)c(C)n[nH]6)c5cc4S(C(C)(C)C)(=O)=O)CC3)nc2)OCC1)=O NNPSDWFWOCDUBT-MUUNZHRXSA-N 0.000 description 1
- KBEDEHFCOANLGZ-UHFFFAOYSA-N CC(C)(C)S(c(c(OCCCN(CC1)CCN1C(C(C=C)=C)=O)c1)cc2c1ncnc2Nc1c(C)c(C)n[nH]1)(=O)=O Chemical compound CC(C)(C)S(c(c(OCCCN(CC1)CCN1C(C(C=C)=C)=O)c1)cc2c1ncnc2Nc1c(C)c(C)n[nH]1)(=O)=O KBEDEHFCOANLGZ-UHFFFAOYSA-N 0.000 description 1
- QKGBTFOMPQNGCH-UHFFFAOYSA-N CC(C)(C)S(c1cc2c(Nc3c(C)c(C)n[nH]3)ncnc2cc1OCCCN(CC1)CCN1c(nc1)ccc1C(O)=O)(=O)=O Chemical compound CC(C)(C)S(c1cc2c(Nc3c(C)c(C)n[nH]3)ncnc2cc1OCCCN(CC1)CCN1c(nc1)ccc1C(O)=O)(=O)=O QKGBTFOMPQNGCH-UHFFFAOYSA-N 0.000 description 1
- ZBJVEMQGMKMUOL-UHFFFAOYSA-N CC(C)(C)S(c1cc2c(Nc3c(C)c(C)n[nH]3)ncnc2cc1OCCN(CC1)CCN1c1ncc(C(O)=O)nc1)(=O)=O Chemical compound CC(C)(C)S(c1cc2c(Nc3c(C)c(C)n[nH]3)ncnc2cc1OCCN(CC1)CCN1c1ncc(C(O)=O)nc1)(=O)=O ZBJVEMQGMKMUOL-UHFFFAOYSA-N 0.000 description 1
- YNKMPUBEOHCOQO-UHFFFAOYSA-N CCCCOc1cc2ncnc(Nc3c(C)c(C)n[nH]3)c2cc1S(C(C)(C)C)(=O)=O Chemical compound CCCCOc1cc2ncnc(Nc3c(C)c(C)n[nH]3)c2cc1S(C(C)(C)C)(=O)=O YNKMPUBEOHCOQO-UHFFFAOYSA-N 0.000 description 1
- BRFRSFUWNSAKTN-VMBXARNFSA-N C[C@H](C1)N(C[C@@H](C2)N(CC(N(CC3(C)C)c4c3ncc(Cc3ccc(C)cc3)c4)=O)C[C@@H](C)N2C(OC(C)(C)C)=O)CCN1C(c1ccc(N2CCN(CCCOc3cc4ncnc(Nc5c(C)c(C)n[nH]5)c4cc3S(C(C)(C)C)(=O)=O)CC2)nc1)=C Chemical compound C[C@H](C1)N(C[C@@H](C2)N(CC(N(CC3(C)C)c4c3ncc(Cc3ccc(C)cc3)c4)=O)C[C@@H](C)N2C(OC(C)(C)C)=O)CCN1C(c1ccc(N2CCN(CCCOc3cc4ncnc(Nc5c(C)c(C)n[nH]5)c4cc3S(C(C)(C)C)(=O)=O)CC2)nc1)=C BRFRSFUWNSAKTN-VMBXARNFSA-N 0.000 description 1
- KXISFLRDVPJYHS-NFBKMPQASA-N C[C@H](CN(CC(N(CC1(C)C)C(C=C2Cc3ccc(C)cc3)=C1NC2=O)=O)[C@@H](CO)C1)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC(N(CC1(C)C)C(C=C2Cc3ccc(C)cc3)=C1NC2=O)=O)[C@@H](CO)C1)N1C(OC(C)(C)C)=O KXISFLRDVPJYHS-NFBKMPQASA-N 0.000 description 1
- PNEVDUPLZBINTR-OAGXKRJSSA-N C[C@H](CN(CC(N(CC1(C)C)c2c1ncc(Cc(cc1)ccc1F)c2)=O)[C@H](C1)C#CN(CC2)[C@H](C)CN2C(NC2C)=NC=C2OCCOc2cc3ncnc(Nc4c(C)c(C)n[nH]4)c3cc2S(C(C)(C)C)(=O)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CN(CC(N(CC1(C)C)c2c1ncc(Cc(cc1)ccc1F)c2)=O)[C@H](C1)C#CN(CC2)[C@H](C)CN2C(NC2C)=NC=C2OCCOc2cc3ncnc(Nc4c(C)c(C)n[nH]4)c3cc2S(C(C)(C)C)(=O)=O)N1C(OC(C)(C)C)=O PNEVDUPLZBINTR-OAGXKRJSSA-N 0.000 description 1
- UMEKYHJOPBYLPD-CLIADVIRSA-N C[C@H]1NC(C[C@H](C2)N(C)CCN2I)CN(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 Chemical compound C[C@H]1NC(C[C@H](C2)N(C)CCN2I)CN(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 UMEKYHJOPBYLPD-CLIADVIRSA-N 0.000 description 1
- CWZDXAGKRYGKPI-LDJSFYOUSA-N C[C@H]1NC[C@H](CN(CC2)C(C)CN2I)N(CC(N2c3cc(Cc(cc4)ccc4F)cnc3C(C)(C)C2)=O)C1 Chemical compound C[C@H]1NC[C@H](CN(CC2)C(C)CN2I)N(CC(N2c3cc(Cc(cc4)ccc4F)cnc3C(C)(C)C2)=O)C1 CWZDXAGKRYGKPI-LDJSFYOUSA-N 0.000 description 1
- FHXRDTNNYDGAJE-CJFMBICVSA-N C[C@H]1NC[C@H](CN(CC2)CCC2I)N(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 Chemical compound C[C@H]1NC[C@H](CN(CC2)CCC2I)N(CC(N(CC2(C)C)c3c2ncc(Cc(cc2)ccc2F)c3)=O)C1 FHXRDTNNYDGAJE-CJFMBICVSA-N 0.000 description 1
- KHYIKINNQSQUOQ-PDXXHEQOSA-N C[C@H]1NC[C@H](CN2C[C@H](C)OCC2)N(CC(N(CCC2)[C@@H]2c2nc(C(c(cc3)ccc3F)=O)c[s]2)=O)C1 Chemical compound C[C@H]1NC[C@H](CN2C[C@H](C)OCC2)N(CC(N(CCC2)[C@@H]2c2nc(C(c(cc3)ccc3F)=O)c[s]2)=O)C1 KHYIKINNQSQUOQ-PDXXHEQOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324944P | 2016-04-20 | 2016-04-20 | |
| US62/324,944 | 2016-04-20 | ||
| PCT/EP2017/059090 WO2017182418A1 (en) | 2016-04-20 | 2017-04-18 | Conjugates comprising ripk2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017253560A1 AU2017253560A1 (en) | 2018-11-08 |
| AU2017253560B2 true AU2017253560B2 (en) | 2019-03-21 |
Family
ID=58548715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017253560A Ceased AU2017253560B2 (en) | 2016-04-20 | 2017-04-18 | Conjugates comprising RIPK2 inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10781205B2 (enExample) |
| EP (1) | EP3445759A1 (enExample) |
| JP (1) | JP2019514878A (enExample) |
| KR (1) | KR20180135038A (enExample) |
| CN (1) | CN109311867A (enExample) |
| AU (1) | AU2017253560B2 (enExample) |
| BR (1) | BR112018071408A2 (enExample) |
| CA (1) | CA3020792A1 (enExample) |
| RU (1) | RU2018134981A (enExample) |
| WO (1) | WO2017182418A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| AU2017313085B2 (en) | 2016-08-19 | 2024-06-20 | Beone Medicines I Gmbh | Use of a combination comprising a Btk inhibitor for treating cancers |
| KR102757960B1 (ko) | 2017-06-26 | 2025-01-22 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
| CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
| CN112533918A (zh) | 2018-06-13 | 2021-03-19 | 安菲斯塔治疗有限责任公司 | 用于靶向Rpn11的双功能分子 |
| CN112533898A (zh) | 2018-07-31 | 2021-03-19 | 日商泛美克斯股份有限公司 | 杂环化合物 |
| CN112638905A (zh) * | 2018-08-28 | 2021-04-09 | 南京明德新药研发有限公司 | 作为rip2激酶抑制剂的喹唑啉类衍生物 |
| CA3133314A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Extracellular vesicle conjugates and uses thereof |
| US12233356B2 (en) | 2019-03-21 | 2025-02-25 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| US20220402935A1 (en) | 2019-07-31 | 2022-12-22 | Fimecs, Inc. | Heterocyclic compound |
| JP2021024787A (ja) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| EP4291193A4 (en) | 2021-02-10 | 2025-05-07 | BeiGene Switzerland GmbH | Egfr degraders and methods of use |
| CN114014890A (zh) * | 2021-03-12 | 2022-02-08 | 爱科诺生物医药(香港)有限公司 | 具有rip2激酶抑制活性的化合物，包含其的药物组合物，及其应用 |
| MX2024008060A (es) | 2021-12-30 | 2024-07-10 | Beigene Switzerland Gmbh | Degradacion de la tirosina quinasa de bruton (btk) mediante conjugacion de inhibidores de la btk con ligando de ligasa e3 y metodos de uso. |
| JPWO2024071371A1 (enExample) * | 2022-09-30 | 2024-04-04 | ||
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| KR20260020383A (ko) | 2023-05-31 | 2026-02-11 | 비원 메디슨즈 아이 게엠베하 | Egfr 키나제의 분해를 위한 화합물 |
| WO2025092821A1 (zh) * | 2023-11-01 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | 喹唑啉衍生物类ripk2抑制剂及其用途 |
| WO2025126115A1 (en) | 2023-12-13 | 2025-06-19 | Beigene Switzerland Gmbh | Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013025958A1 (en) * | 2011-08-18 | 2013-02-21 | Glaxo Group Limited | Amino quinazolines as kinase inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110218A1 (es) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| HRP20140885T1 (hr) | 2007-04-13 | 2014-11-21 | The Regents Of The University Of Michigan | Diazo bicikliäśki smac mimetici i njihove primjene |
| WO2009140447A1 (en) * | 2008-05-16 | 2009-11-19 | Novartis Ag | Immunomodulation by iap inhibitors |
| BR112012003118A2 (pt) | 2009-08-12 | 2016-02-23 | Novartis Ag | formulações orais sólidas e formas cristalinas de um inibidor de proteína apoptose |
| ES2552977T3 (es) | 2010-05-07 | 2015-12-03 | Glaxosmithkline Intellectual Property Development Limited | Amino-quinolinas como inhibidores de quinasa |
| UY33549A (es) | 2010-08-10 | 2012-01-31 | Glaxo Group Ltd | Quinolil aminas como agentes inhibidores de las quinasas |
| WO2012122011A2 (en) * | 2011-03-04 | 2012-09-13 | Glaxosmithkline Llc | Amino-quinolines as kinase inhibitors |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| ES2654623T3 (es) | 2012-08-23 | 2018-02-14 | The Regents Of The University Of Michigan | Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan |
| TW201425307A (zh) | 2012-09-13 | 2014-07-01 | Glaxosmithkline Llc | 作為激酶抑制劑之胺基－喹啉類 |
| WO2014047024A1 (en) | 2012-09-18 | 2014-03-27 | Bristol-Myers Squibb Company | Iap antagonists |
| US9603889B2 (en) | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9409888B2 (en) | 2012-12-11 | 2016-08-09 | Hoffmann-La Roche Inc. | Dimeric compounds |
| KR101335240B1 (ko) | 2012-12-13 | 2013-11-29 | 전호건 | 수평 연속 방식의 탄화장치 |
| TWI630203B (zh) | 2013-02-21 | 2018-07-21 | 葛蘭素史克智慧財產發展有限公司 | 做為激酶抑制劑的喹唑啉類 |
| GB201311891D0 (en) * | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) * | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| WO2015092420A1 (en) | 2013-12-20 | 2015-06-25 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201506872D0 (en) * | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201506871D0 (en) * | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
-
2017
- 2017-04-18 CA CA3020792A patent/CA3020792A1/en not_active Abandoned
- 2017-04-18 RU RU2018134981A patent/RU2018134981A/ru not_active Application Discontinuation
- 2017-04-18 EP EP17717721.9A patent/EP3445759A1/en not_active Withdrawn
- 2017-04-18 AU AU2017253560A patent/AU2017253560B2/en not_active Ceased
- 2017-04-18 WO PCT/EP2017/059090 patent/WO2017182418A1/en not_active Ceased
- 2017-04-18 CN CN201780036566.1A patent/CN109311867A/zh active Pending
- 2017-04-18 US US16/094,564 patent/US10781205B2/en not_active Expired - Fee Related
- 2017-04-18 KR KR1020187033631A patent/KR20180135038A/ko not_active Withdrawn
- 2017-04-18 BR BR112018071408A patent/BR112018071408A2/pt not_active Application Discontinuation
- 2017-04-18 JP JP2018555185A patent/JP2019514878A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013025958A1 (en) * | 2011-08-18 | 2013-02-21 | Glaxo Group Limited | Amino quinazolines as kinase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180135038A (ko) | 2018-12-19 |
| JP2019514878A (ja) | 2019-06-06 |
| RU2018134981A (ru) | 2020-05-20 |
| EP3445759A1 (en) | 2019-02-27 |
| US20190119271A1 (en) | 2019-04-25 |
| CN109311867A (zh) | 2019-02-05 |
| CA3020792A1 (en) | 2017-10-26 |
| US10781205B2 (en) | 2020-09-22 |
| BR112018071408A2 (pt) | 2019-02-05 |
| WO2017182418A1 (en) | 2017-10-26 |
| AU2017253560A1 (en) | 2018-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10781205B2 (en) | Conjugates comprising RIPK2 inhibitors | |
| AU2016252404B2 (en) | Novel compounds | |
| JP7603609B2 (ja) | アンドロゲン受容体を標的に分解する二官能性キメラ複素環式化合物及びその使用 | |
| ES2950569T3 (es) | (S)-4-(8-amino-3-(1-(but-2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-2-metoxi-n-(piridin-2-il)benzamida como inhibidor de la Btk | |
| AU2014324595B2 (en) | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| ES2609087T3 (es) | Derivado de dihidropirazolopirimidinona | |
| ES2654288T3 (es) | Moduladores de P2X7 | |
| KR20200096571A (ko) | 질병의 치료를 위한 신규 화합물 및 그의 약학 조성물 | |
| CA2906085A1 (en) | P2x7 modulators | |
| US20250136595A1 (en) | Acylated heterocyclic quinazoline derivatives as inhibitors of erbb2 | |
| EP3746432B1 (en) | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
| US12486267B2 (en) | Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis | |
| CA3123699A1 (en) | Thienopyridinone compounds | |
| SG11202105913RA (en) | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
| ES2906956T3 (es) | Derivados de oxepinopirazol como inhibidores de la actividad de PI3-cinasa | |
| EP3727380B1 (en) | Purine inhibitors of human phosphatidylinositol 3-kinase delta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |